Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Launched by SANTA CHIARA HOSPITAL · Jan 17, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called olaparib on men with a specific type of prostate cancer known as metastatic castration-resistant prostate cancer (mCRPC). The goal is to understand how well olaparib works in real-life situations, including overall survival rates and other important health outcomes for patients who have a genetic change known as a BRCA mutation.
To participate in this study, men must have metastatic castration-resistant prostate cancer and be receiving olaparib treatment in a regular clinical setting, not as part of a clinical trial. The study is currently recruiting participants, and men who qualify will have the opportunity to contribute to important research that could help shape future treatments. Participants can expect to be part of a comprehensive review of how olaparib is used and its effects on their health, which may provide valuable information for themselves and others facing similar health challenges.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
- Exclusion Criteria:
- • Olaparib treatment in a clinical trial
About Santa Chiara Hospital
Santa Chiara Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a focus on multidisciplinary collaboration, the hospital serves as a vital center for clinical research across various therapeutic areas. Leveraging state-of-the-art facilities and a team of experienced healthcare professionals, Santa Chiara Hospital aims to contribute to the development of new treatments and therapies, ensuring that patients have access to the latest advancements in medicine. Through rigorous adherence to ethical standards and regulatory guidelines, the hospital fosters a research environment that prioritizes patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Napoli, , Italy
Trento, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported